Idenix Pharma (DIX) Says IDX184 Demonstrated High Level of Resistance to In Vitro, Antiviral Acitivity

Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), has announced interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection. IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies.

For more color, click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• Biogen (BIIB) Receives Positive CHMP Opinion for TOFIDENCE
• VinFast Auto (VFS) Appoints Tham Chee Soon to its Board, Ngan Wan Sing Winston Resigns